You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent, selective dopamine D2 and D3 receptor antagonist. Ki values are 2.8 and 3.2 nM respectively for human D2 and D3 and > 1000 nM for human D1, D4 and D5 receptors. Shows selectivity for presynaptic dopamine autoreceptors at low doses and blocks postsynaptic D2/D3 receptors at higher doses. Preferentially interacts with limbic D2-like receptors in vivo. Atypical antipsychotic/antischizophrenic agent with limited extrapyrimidal side effects and a profile distinct from that of haloperidol and remoxipride.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|1eq. HCl||9.24||25 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 369.48. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.41 mL||27.07 mL||54.13 mL|
|2.5 mM||1.08 mL||5.41 mL||10.83 mL|
|5 mM||0.54 mL||2.71 mL||5.41 mL|
|25 mM||0.11 mL||0.54 mL||1.08 mL|
References are publications that support the biological activity of the product.
Perrault et al (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 DA receptor antagonist activity and limbic selectivity. J.Pharmacol.Exp.Ther. 280 73 PMID: 8996184
Schoemaker et al (1997) Neurochemical characteristics of amisulpride, an atypical DA D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J.Pharmacol.Exp.Ther. 280 83 PMID: 8996185
Moller (2003) Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog.Neuro-Psychopharm.Biol.Psychiat. 27 1101
If you know of a relevant reference for Amisulpride, please let us know.
View Related Products by Product Action
Keywords: Amisulpride, Amisulpride supplier, Selective, D2/D3, receptor, antagonists, atypical, antipsychotic, agent, Dopamine, D2-like, Non-Selective, Receptors, dopaminergic, DAN2163, DAN, 2163, Non-selective, 2132, Tocris Bioscience
2 Citations for Amisulpride
Citations are publications that use Tocris products. Selected citations for Amisulpride include:
Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643
Midkiff et al (2011) Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PLoS One 6 e25395 PMID: 21966518
Do you know of a great paper that uses Amisulpride from Tocris? Please let us know.
Reviews for Amisulpride
There are currently no reviews for this product. Be the first to review Amisulpride and earn rewards!
Have you used Amisulpride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.